Sally struthers returns

@BIOTECHSCANNER @TheLastGerman24 Next catalyst that moves the needle ? Revenue guidance ?

@TheLastGerman24 Soon

$IOVA is a gift at the current levels $3.80-$4. It will be over $10 by end of year. There are so many massive catalysts coming. Most importantly, Amtagvi adoption is accelerating and that means when NSCLC is approved sales will be through the roof. The sales and marketing infrastructure is already being built and fine tuned with the advanced melanoma indication. It will be a well oiled machine soon. Patience…

@lukemorgan75 @BIOTECHSCANNER I loaded up more today. I have one more load left if it dips lower. Alot of Jan and September calls at 5

@BIOTECHSCANNER Ready to buy more with the profits from my options if it goes down to the $3.50 level.

@TheLastGerman24 @BIOTECHSCANNER I added a lot today

@BIOTECHSCANNER Bought at 5€ per Stock... Im deep red. Hope this shit skyrockets one day.

@BIOTECHSCANNER Wendy Yarno stepping down. A nothing burger or anything you take from it ?

$IOVA - More hiring happening almost on a weekly basis. Amtagvi demand acceleration? Nah, they just hire new people for fun.

all because this douchebag @johnarnold doesn't think rare disease patients' lives are worth anything easy to say until it is your family member who has DMD, SMA, CF, HD, etc.

@kainvests How do 3.19 million shares get purchased and no pop in price?

$IOVA And I’m definitely not the only one buying the dips 😉

$IOVA Dip bought and added in a separate investment account where I’ll be holding shares beyond 2027/2028. The weekend is here, time to disconnect and live a little. 🤍

In a landmark medical technology milestone, a fully autonomous AI-powered robotic dentist — built by US company Perceptive — completed a full crown preparation on a human patient in just 15 minutes. The same procedure typically takes a human dentist 2–2.5 hours. The robot used real-time 3D scanning, AI decision-making, and a precision robotic arm to perform the entire procedure without any human guidance or intervention mid-surgery. This isn't a concept or prototype — it's already been performed on real patients and a peer-reviewed study was published in the Journal of Dentistry in January 2026. Experts say this is the beginning of a transformation: robotic dentists could eliminate human error, work at any hour, and eventually bring high-quality dental care to remote and underserved communities where trained dentists are unavailable. The dental office of 2035 may look very different from today's.

@BIOTECHSCANNER Amazing year ahead! The Q4 was my biggest prove for $IOVA in 2026 and beyond ☝🏽

$IOVA - These numbers are staggering. 234,600 new cases in the US ALONE. Iovance will be there. This is why I don’t ever worry about “competition.” We actually need more treatment options to meet demands. It’s about the patient first and foremost. Remember, 90% of all new cancers are solid tumors. $IOVA can’t do it alone. Iovance Biotherapeutics is becoming a household name in this space. 2026 and beyond will be amazing for this company and the patients who will be saved! Iovance will become big pharma soon.

$IOVA Taking a look at Iovance thru the lens of current world events: 1) Higher oil prices - energy is a very small input for Iovance so no impact on margins 2) Tariffs - manufacturing is in US and infrastructure built out to handle 5,000 patients/ year so no need for material rise in input costs 3) War with Iran/potential recession - Amtagvi approved and all treatment in US so world events limited. Cancer does not wait for a war to end or for the economy to improve. Healthcare and biotech are usually the safe haven when the market gets dicey because they are, for the most part, a non-cyclical sector.

@YodaStockInvest $IOVA

$IOVA (L) 30-40% pullbacks in strong momentum names are some of my favorite entry setups. That said, $XBI looks like it's rolling over here, so broader market risk is high. Love $IOVA though; if Amtagvi proves out in NSCLC later this year, the sky is the limit

$IOVA We thought the week was set, but it wasn’t! Last week we discussed about Immutep discontinuing their NSCLC trial, a near direct competitor to Iovance’s TIL therapy. And here we are today before the news that this time it is AstraZeneca discounting a trial that could have been direct competition to TIL in the solid tumour realm. Things are aligning across the board! Internally and externally. And here we are, in a Triple Witching day that could bring us further discounts! Source: fiercebiotech.com/biotech/pfizer… 🤍 Thank you babariaron on StockTwits for the awesome share!

$IOVA- looks ready for a violent rebound here

@Henry431171040 @BiotechAutist @Investorclimber Absolutely but short term could create a dip. I think it two years they will struggle on the supply side unless they get bought out. Demand will be so massive.

@Dancingtapas @BiotechAutist @Investorclimber They also will only compete for 2l so once tilvance 301 is unlocked , its a nothing burger

$ALDX Boom

@KingachillesE @A_May_MD They finally started to have decent margins in 2026.

@A_May_MD I’m with you on COGS being an issue, however still early days. They have tightened things up in terms of process. As you note it’s quite complicated. I am a trader in this name mostly (because of opportunity), but long term investor as well. THIS MOVE IS OVERDONE.

If you’re long $IOVA and only listening to the permabull biotwitter cult leading pumpers who won’t stop tweeting about how positive the earnings results were, you may be wondering why you’re down 20% right now. Well, it *does* happen that stocks irrationally trade down on good news sometimes. But you may want to be open to the idea that the earnings actually weren’t positive and take a look at how expensive these $IOVA revenues are. Especially the fact that $8.3M was “wasted” on manufacturing Amtagvi that was never given to patients. This is an EXTREMELY intense and complicated regimen to administer. There will be manufacturing failures, people will drop out electively or even die during preconditioning (or from advanced disease) before getting Amtagvi. The result of these problems is spending a LOT of money on making product that never generates any revenue. A double whammy. Sure, total revenue exceeded some sellside projects this quarter. But that $8.3M loss just on “wasted” manufacturing accounts for almost 20% of all Amtagvi revenues on the quarter! How many sellside projections have $IOVA immediately dumping 20% of Amtagvi revenue into the trash? Not good. Quit listening to the permabull pumpers and consider that it’s possible things actually aren’t going well. Fingers crossed for good NSCLC data this weekend, which could certainly turn things around if resoundingly positive.

@Henry431171040 @BiotechAutist @Investorclimber The only potential competition is Repl a little bit for melanoma

@Dancingtapas @BiotechAutist @Investorclimber Yeah 10Bil potential for Iovance. Crazy thing is Immutep gave up NSCLC study, AstraZencea failed their NSCLC . Iovance has no competitor aka the first and only immunotherapy if approved in 2027.

@Henry431171040 @BiotechAutist @Investorclimber Agreed just wondering how much cash to have on the sidelines for the possibility of that bump caused by the noise. Have a nice position already.

@Dancingtapas @BiotechAutist @Investorclimber This will be 12+ anyways the moment it filed sBLA for NSCLC so. All esle is noise and opportunity to buy. Teens is inevitable